Sign up United Kingdom
HemoGenyx Pharmaceuticals (LON:HEMO)

HemoGenyx Pharmaceuticals (LON:HEMO)


Share Price
2.73 p
Change
-0.125 (-4.39 %)
Market Cap
£9.81 m
Proactive Investors - Run By Investors For Investors

HemoGenyx Pharmaceuticals

HemoGenyx Pharmaceuticals is headquartered in London, with its wholly owned US operating subsidiary, HemoGenyx LLC, located in Brooklyn, New York at its state- of- the- art research facility ("HemoGenyx"). HemoGenyx is a preclinical-stage biotechnology company focused on the discovery, development and commercialisation of novel therapies and treatments for blood diseases, like leukemia and...

EPIC: HEMO
Market: LSE:HEMO
52-week High/Low: 6.80p / 2.00p
Sector: Nonequity Investment Instruments
Market Cap: 9.81M
Website: www.hemogenyx.com

HemoGenyx Pharmaceuticals

www.hemogenyx.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in HemoGenyx Pharmaceuticals


HemoGenyx Pharmaceuticals Snapshot

Rich pipeline of products

We are building a rich pipeline of products in two major spaces: – cell therapy and immunotherapy.

Advanced product candidate

Our most advanced product candidate is in the process of completing its pre-IND consultation programme in readiness for the start of Phase 1 clinical trials within 24 months.

Highly experienced team

We have assembled a highly experienced team of experts to advance our pipeline of cell therapies and immunotherapies into the clinical arena.

State-of-the-art research facilities

Our state-of-the-art research laboratory allows us to move rapidly from discovery through preclinical development toward clinical trials.

Our passionate mission

We believe that we can transform patients' lives by delivering breakthrough therapies. We also believe that good business means healthy people and a better world.

To develop new therapies that are based on breakthrough science

To bring hope to patients with serious or life threatening diseases

To treat life threatening diseases, bringing societal benefit

To realize unique treatment opportunities for patients and value for investors

TECHNOLOGY
A new era for the treatment of blood diseases

How it works

BM/HSC transplants includes a number of procedures whereby the BM/HSC of a patient are depleted and then replaced with hematopoietic stem/progenitor cells (HSPC) derived from the patient him/herself (Autologous HSCT) or from a donor (Allogeneic HSCT). Every BM/HSC transplant can be subdivided into three major stages. HemoGenyx's technologies target the first two stages where the greatest risks and limitations are, as shown below. Hemogenyx's technologies are complementary, but can also be used as stand alone products in line with traditional methods.

 

STEP 1


Administration of CDX Bi-specific antibody
CDX antibodies will be developed as a stand-alone off-the-shelf product ready for intravenous (IV) injection. The antibodies will be injected once or several times (most likely up to three times) within a predetermined period (most likely 1 to 5 days). Learn more 

STEP 2 

Hu-PHEC
Hu-PHEC isolated from either umbilical cord and placenta (allogeneic) or the liver of a patient (autologous) will be used for transplantation. When transplanted, Hu-PHEC will regenerate the blood system of a patient. Learn More

STEP 3 

Engraftment and Recovery
A patient will remain in hospital while the new cells grow and regenerate their blood system, white blood cells and platelets. The patient's immune system will be delicate during this period and thus will be in a germ free environment.

Dr Vladislav Sandler
Ph.D.
CHIEF EXECUTIVE OFFICER AND CO-FOUNDER

Dr Robin Campbell
CHAIRMAN

Lawrence Pemble
CHIEF OPERATING OFFICER

Alexis M. Sandler
NON-EXECUTIVE DIRECTOR AND CO-FOUNDER

Peter Redmond
NON-EXECUTIVE DIRECTOR

Adrian Beeston
NON-EXECUTIVE DIRECTOR

Sir Marc Feldmann
AC FAA FRS FRCP FRCPath FMedSci
CHAIRMAN OF THE ADVISORY BOARD / SCIENTIFIC ADVISOR

As at 5 October 2017, the number of shares in issue was 356,042,854.

SIGNIFICANT SHAREHOLDERS

  On the date of Admission
Shareholder Number Ordinary
Shares %
Flascherberg Capital Anstalt 27,996,487 7.86
Craig Auringer 31,407,913 8.82
Ron Valk 17,131,193 4.81
Plum Capital 11,692,863 3.28
43 North LLC 11,371,429 3.19
 

 

UK HEADQUARTERS


5 Fleet Place, London, EC4M 7RD, United Kingdom

email - [email protected]

RESEARCH FACILITY


760 Parkside Ave. Ste. 212 Brooklyn, NY 11226, US
email - [email protected]

MEDIA & INVESTOR RELATIONS


Walbrook PR Ltd. 4 Lombard St, London EC3V 9HD, United Kingdom
+44 (0)20 7933 8780
email - [email protected]

REGISTERED OFFICE

5 Fleet Place
London
EC4M 7RD

JOINT BROKER

Optiva Securities Limited
2 Mill Street
Mayfair
London
W1S 2AT

JOINT BROKER

Shard Capital Partners LLP
23rd Floor
20 Fenchurch Street
London
EC3M 3BY

RULE 3 ADVISER AND FINANCIAL ADVISER

Peterhouse Corporate Finance Limited
3rd Floor
New Liverpool House
15 Eldon Street
London
EC2M 7LD

AUDITORS AND REPORTING ACCOUNTANTS

PKF Littlejohn LLP
Westferry Circus
Canary Wharf
London
E14 4HD

REGISTRAR

Computershare Investor Services PLC
The Pavilions
Bridgwater Road
Bristol
BS13 8AE

LEGAL ADVISERS TO THE COMPANY AS TO ENGLISH LAW

Charles Russell Speechlys LLP
5 Fleet Place
London
EC4M 7RD

LEGAL ADVISERS TO THE COMPANY AS TO US LAW

Rubin & Rudman LLP
50 Rowes Wharf
Boston
Massachusetts 0211

FINANCIAL PR AND INVESTOR RELATIONS

Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD

Tel: 020 7933 8780
Email: [email protected]

HemoGenyx Pharmaceuticals Timeline

RNS
June 27 2018
RNS
June 08 2018
RNS
May 14 2018
RNS
April 30 2018
RNS
April 11 2018
RNS
April 03 2018
RNS
March 14 2018
Video
January 11 2018

Market Reports Including HEMO

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use